(For the year ended March 2023)
KEYWORD
Overseas
Employees
We have a total of 14,484 active employees
(Astellas group total).
Total sales revenue
(For the year ended March 2023)
Revenue ratio to sales
R&D Expense to Revenue Ratio
We invest 18% of sales revenue development costs in R&D. We aim to achieve sustainable growth by creating novel innovative drugs.(For the year ended March 2023)
R&D Expenses
R&D expenses totaled
224.5 billion yen(For the year ended March 2023)
Major pipeline(number of programs)
Rx:Prescription drug
Rx+®:Innovative healthcare solutions that build
upon Astellas’ strengths in prescription drugs
(end of FY2023; only for Astellas Pharma Inc.)
Get informed about the working environment
Average age
(end of FY2023; only for Astellas Pharma Inc.)
Average length of service
(end of FY2023; only for Astellas Pharma Inc.)
Overtime work hours per month
(end of FY2023; only for Astellas Pharma Inc.)
Percentage of paid leave taken
(end of FY2023; only for Astellas Pharma Inc.)
Percentage of holidays and leave taken for childcare or nursing care
(end of FY2023; only for Astellas Pharma Inc.)
(end of FY2023; only for Astellas Pharma Inc.)
Employees who run a sideline business
(end of FY2023; only for Astellas Pharma Inc.)